Myo-inositol in assisted reproductive technology from bench to bedside.
D-chiro-inositol
assisted reproductive technology
in vitro fertilization
infertility
myo-inositol
polycystic ovary syndrome
Journal
Trends in endocrinology and metabolism: TEM
ISSN: 1879-3061
Titre abrégé: Trends Endocrinol Metab
Pays: United States
ID NLM: 9001516
Informations de publication
Date de publication:
01 2024
01 2024
Historique:
received:
05
05
2023
revised:
14
09
2023
accepted:
15
09
2023
medline:
11
1
2024
pubmed:
6
10
2023
entrez:
5
10
2023
Statut:
ppublish
Résumé
Inositols are insulin-sensitizing compounds of promising efficacy in the management of polycystic ovary syndrome (PCOS). On the one hand, myo-inositol (myo-ins) plays a regulatory role in male and female reproductive function, influencing the development of oocytes, spermatozoa, and embryos. On the other hand, high concentrations of D-chiro-inositol (D-chiro-ins) in the ovary may adversely affect oocyte quality. This review analyses the available literature, which encourages the clinical use of myo-ins in assisted reproductive technologies (ARTs) due to its beneficial effects on female and male reproduction.
Identifiants
pubmed: 37798243
pii: S1043-2760(23)00194-7
doi: 10.1016/j.tem.2023.09.005
pii:
doi:
Substances chimiques
Inositol
4L6452S749
Insulin
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
74-83Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests V.U. is employed at Lo.Li. Pharma Srl, Rome, Italy. All other authors have nothing to declare.